Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

NCT04604067 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: Acalabrutinib

Sponsor

Swiss Cancer Institute